Insider Transactions in Q1 2022 at Nu Skin Enterprises, Inc. (NUS)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 22
2022
|
Andrew D Lipman Director |
SELL
Open market or private sale
|
Direct |
1,000
-1.37%
|
$47,000
$47.4 P/Share
|
|
Mar 09
2022
|
Edwina D Woodbury Director |
BUY
Grant, award, or other acquisition
|
Direct |
12
+0.09%
|
$564
$47.9 P/Share
|
|
Mar 02
2022
|
Joseph Y Chang Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,423
-6.67%
|
$157,458
$46.2 P/Share
|
|
Mar 02
2022
|
Joseph Y Chang Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,423
+11.49%
|
$102,690
$30.63 P/Share
|
|
Mar 01
2022
|
Joseph Y Chang Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
28,577
-28.08%
|
$1,285,965
$45.63 P/Share
|
|
Mar 01
2022
|
Joseph Y Chang Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,577
+35.67%
|
$857,310
$30.63 P/Share
|
|
Feb 25
2022
|
Ryan S Napierski President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-8.8%
|
$1,175,000
$47.49 P/Share
|
|
Feb 25
2022
|
Ryan S Napierski President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+7.88%
|
$850,000
$34.11 P/Share
|
|
Feb 25
2022
|
Ryan S Napierski President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
31,613
+20.49%
|
-
|
|
Feb 25
2022
|
Connie Mang Yee Tang Chief Global Growth Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,147
+24.93%
|
-
|
|
Feb 25
2022
|
Mark H Lawrence Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,381
+17.38%
|
-
|
|
Feb 25
2022
|
Joseph Y Chang Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,744
+22.71%
|
-
|
|
Feb 25
2022
|
Chayce David Clark EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
8,430
+26.37%
|
-
|
|
Feb 25
2022
|
Steven Keith Hatchett Chief Product Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,901
+9.63%
|
-
|
|
Feb 25
2022
|
James D Thomas Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,557
+37.4%
|
-
|
|
Feb 22
2022
|
Andrew D Lipman Director |
SELL
Open market or private sale
|
Direct |
1,000
-1.35%
|
$53,000
$53.27 P/Share
|
|
Feb 15
2022
|
Ryan S Napierski President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,498
-4.71%
|
$220,402
$49.65 P/Share
|
|
Feb 15
2022
|
Mark H Lawrence Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,139
-10.74%
|
$251,811
$49.65 P/Share
|
|
Feb 15
2022
|
Joseph Y Chang Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,729
-9.64%
|
$84,721
$49.65 P/Share
|
|
Feb 15
2022
|
Chayce David Clark EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
865
-5.41%
|
$42,385
$49.65 P/Share
|
|
Feb 15
2022
|
James D Thomas Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
799
-12.17%
|
$39,151
$49.65 P/Share
|
|
Feb 15
2022
|
Steven Keith Hatchett Chief Product Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,021
-2.02%
|
$50,029
$49.65 P/Share
|
|
Jan 24
2022
|
Andrew D Lipman Director |
SELL
Open market or private sale
|
Direct |
1,000
-1.33%
|
$50,000
$50.5 P/Share
|